In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be “Yes”:

☐ Does the activity align with Pfizer’s areas of interest? (listed on pages 2-8 of this document)

☐ Is it a live* annual activity which serves as a platform for the exchange of new clinical and scientific information and reaches a national or regional audience?

   *Live CME/CE activities are defined as any activity which incorporates the opportunity for live real-time learner interaction such as live meetings, e-learning and live non-enduring web-casts/webinars

☐ Is this activity developed by your organization specifically for your professional members or constituents?

☐ Is the activity established part of your organization’s ongoing educational program? If not, if it is a new activity, is it clearly based on an assessment of the educational needs of your target audience?

<table>
<thead>
<tr>
<th>Application Cycle</th>
<th>To Submit Live Activity Must Start On or After</th>
<th>Decision Communicated By*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 1 - Feb 15</td>
<td>Apr 1</td>
<td>Mar 11</td>
</tr>
<tr>
<td>Mar 1 - Apr 15</td>
<td>Jun 1</td>
<td>May 12</td>
</tr>
<tr>
<td>May 1 - June 15</td>
<td>Aug 1</td>
<td>July 12</td>
</tr>
<tr>
<td>July 1 - Aug 15</td>
<td>Oct 1</td>
<td>Sept 10</td>
</tr>
<tr>
<td>Sept 1 - Oct 31</td>
<td>Dec 1</td>
<td>Nov 17</td>
</tr>
</tbody>
</table>

If your activity is in..... Latest* Date to submit to Pfizer is....

<table>
<thead>
<tr>
<th></th>
<th>Latest* Date to submit to Pfizer is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>April or May 2015</td>
<td>February 15</td>
</tr>
<tr>
<td>June or July 2015</td>
<td>April 15</td>
</tr>
<tr>
<td>August or September 2015</td>
<td>June 15</td>
</tr>
<tr>
<td>October or November 2015</td>
<td>August 15</td>
</tr>
<tr>
<td>December 2015 or January, February or March 2016</td>
<td>October 31</td>
</tr>
</tbody>
</table>

*This is the latest date to submit. Your request will be reviewed if submitted in an earlier cycle.

Questions? Email IGLC@pfizer.com
Acromegaly

Improve the knowledge base of health care providers, educators and third party payers working in the area of acromegaly.

Acute Kidney Injury

Close gaps in knowledge for the progression of the pathophysiology, clinical manifestations and survival.

Attention Deficit Hyperactivity Disorder (ADHD)

Improve the healthcare providers’ understanding of the appropriate diagnosis, treatment and management of ADHD in the primary and specialty care settings.

Cardiovascular Metabolic Risk

Cardiovascular Risk Reduction: Focus on Lipids

- For research clinicians and scientists, facilitate scientific dialogue and the exchange of new research and data in the area of lipid lowering, including PCSK9 inhibition
- For healthcare providers working in the areas of primary care, cardiology, and endocrinology, increase the awareness and understanding of:
  - the significant CV risk that persists despite using the current lipid lowering standard of care, with a focus on patients at high CV risk, heterozygous familial hypercholesterolemia (FH), as well as statin intolerant patients, and
  - the new emerging research and mechanisms of action in the area of lipid lowering, including PCSK9 inhibition

Diabetes and Obesity

Improve healthcare provider awareness of current and emerging evidence-based treatments for obese and/or diabetic patients, and also for patients at risk of developing these diseases.

Questions? Email IGLC@pfizer.com
Diabetic Nephropathy

Close gaps in knowledge for the progression of the pathophysiology, clinical manifestations and survival.

Diabetic Peripheral Neuropathy

Translate knowledge of the consequences of Diabetic Peripheral Neuropathy (DPN) into effective treatment strategies that are appropriate in the context of overall diabetes management.

Dietary Supplements

- Improve the healthcare provider’s ability to advise and counsel patients on the prevalence of nutritional gaps even amongst consumers with a healthy diet and the roles of MVMs designed to fill nutritional gaps
- Increase the healthcare provider's ability to advise and counsel patients on the importance of diet and nutrition, particularly in the areas of bone, muscle and joint health. To educate physicians on prevalence of osteoporosis and importance of maintaining mobility.

Duchenne Muscular Dystrophy

Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

Epilepsy

Improve the understanding of the pathophysiology and differential diagnosis of seizures among neurologists and translate their knowledge of the available pharmacological treatment options and strategies to practice.

Fibromyalgia

Improve awareness of appropriate evidence-based treatment as well as the management of patient expectations in improving patient outcomes for fibromyalgia.

Questions? Email IGLC@pfizer.com
Gene Therapy

Close knowledge gaps regarding gene therapy applications for Cystic Fibrosis, Duchenne Muscular Dystrophy, Friedreich’s Ataxia, Hemophilia and Spinal Muscular Atrophy.

Glomerulonephritis

Close knowledge gaps regarding the progression of the pathophysiology, clinical manifestations and survival.

Hemophilia

Facilitate enhanced coordination of care and communication between patients with hemophilia and doctors, and ensure practitioners know how to safely treat and monitor these patients.

Infectious Disease

Vaccine Preventable Diseases

- Improve immunization across the life span by addressing perceptions of younger healthcare providers related to immunizations in general.
- Improve the care of pediatric patients by
  - Highlighting the disparity between family physicians and pediatricians in adherence to recommended childhood vaccination schedule
  - Exploring gaps in the healthcare system that negatively impact the burden of invasive pneumococcal disease and search for ways to minimize these gaps
- Improve the care of adolescent/young adult patients by
  - Increasing awareness of the changing epidemiology as well as the morbidity and mortality of meningococcal disease in adolescents
  - Increasing awareness of adolescent national vaccination guidelines
  - Increasing the percentage of adolescents receiving national guideline recommended immunizations
- Improve the care of adult patients by

Questions? Email IGLC@pfizer.com
o Increasing awareness of the changing epidemiology of pneumococcal disease in adults
o Increasing awareness of national adult vaccination guidelines
o Increasing the percentage of adults receiving national guideline recommended immunizations

**Inflammatory bowel disease (IBD)**

Improve the care of patients with inflammatory bowel disease (IBD) by increasing healthcare provider knowledge of the pathophysiology of IBD and emerging strategies for therapy.

**Lysosomal Storage Diseases**

Improve positive outcomes in patients with Lysosomal Storage Diseases by facilitating enhanced coordination of care and communication between multidisciplinary teams of healthcare professionals, ensuring practitioners know how to safely treat and monitor patients.

**Migraine**

Improve the healthcare provider’s understanding of the diagnosis and treatment of Migraine.

**Oncology**

**Acute Lymphoblastic Leukemia (ALL)**

For hematologists, oncologists and all healthcare professionals involved in the care and treatment of patients with ALL, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and the potential use of novel targeted agents for the treatment of ALL, either alone or in combination with chemotherapy.

**Breast Cancer**

For oncologists and all healthcare professionals involved in the care and treatment of patients with advanced or metastatic breast cancer, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines for the treatment of metastatic breast cancer; in particular ER+ cancer and advances in CDK 4/6 inhibition.

Questions? Email IGLC@pfizer.com
**Chronic Myelogenous Leukemia (CML)**

For hematologists, oncologists and all healthcare professionals involved in the care and treatment of patients with CML, increase understanding of the importance of achieving optimal treatment response through adequate testing customization and results interpretation, improve their ability to maintain patient on treatment by proactive and reactive toxicity management, optimize treatment sequencing, and improve patient outcomes.

**Gastrointestinal Stromal Tumors (GIST) and Pancreatic Neuroendocrine Tumors (pNET)**

For oncologists and all healthcare professionals involved in the care and treatment of patients with GIST or pNET, increase understanding of when novel targeted therapies should be considered for patients with progressive or advanced disease.

**Non-Small Cell Lung Cancer (NSCLC)**

For oncologists, pulmonologists, pathologists, surgeons, interventional radiologists, and all healthcare professionals involved in the care and treatment of patients with NSCLC, increase the awareness and understanding of the importance of treating patients based on the timely results of molecular testing (e.g. ALK, EGFR) in order to optimize patient outcomes.

**Renal Cell Carcinoma (RCC)**

For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to patient care, especially with respect to sequencing, scheduling, dosing, use of combination therapies, and management of side effects.

**General Oncology - Basic Science and Clinical Research Interests**

Through the academic exchange of research and ideas, enhance the discovery and translation of novel cancer therapies, increase scientific understanding of their mechanisms-of-action as well as the efficacy, safety, and potential clinical applicability. Topics of interest include anti-angiogenesis, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, immunotherapy, checkpoint inhibitors, biosimilars, and antibody drug conjugates.

*Questions? Email IGLC@pfizer.com*
Pfizer Independent Grants for Learning & Change
Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

Pain

- Improve awareness of appropriate evidence-based treatment as well as the management of patient expectations in improving care for patients with chronic pain
- Improve patient care by increasing the knowledge, competence, and performance of clinicians who are treating or considering treatment of pain with opioids
- Improve patient care by increasing the healthcare provider’s understanding of all available therapeutic options, both prescription and over the counter, in the continuum of pain care

Psoriasis

Improve the care of patients with psoriasis by increasing healthcare provider knowledge of the pathophysiology of psoriasis and psoriatic arthritis, as well as its implications for mechanism of action of emerging therapies.

Rheumatoid Arthritis

- Improve the care of Rheumatoid Arthritis patients by increasing the knowledge of the pathophysiology of Rheumatoid Arthritis and its implications for mechanism of action of emerging therapies
- Increase healthcare provider knowledge of emerging inflammation therapies

Sickle Cell

Improve healthcare provider’s knowledge of diagnosis and treatment of sickle cell disease and facilitate enhanced coordination of care and communication between patients with sickle cell disease and healthcare providers.

Smoking Cessation

Increase the number of patients who stop smoking by improving the frequency and effectiveness of smoking cessation intervention, including treatment, counseling and support, by healthcare providers.

Questions? Email IGLC@pfizer.com
Spinal Muscular Atrophy
Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

TTR Amyloidoses
Close knowledge gaps regarding the progression of the pathophysiology, clinical manifestations and survival.

Urology

Overactive bladder
Increase positive outcomes for both male and female patients with overactive bladder by improving the healthcare provider’s knowledge, attitude, communication skills, and resources to provide behavioral modification support and optimal medical treatment.

Women’s Health

Menopause
Improve healthcare professionals’ knowledge and ability to provide individualized, evidence-based, and optimum management of conditions that are prevalent in postmenopausal women, such as vulvar and vaginal atrophy, vasomotor symptoms, and osteoporosis.

Support for the CME/CE/CPD Profession and Under-represented Healthcare Professionals
This category supports live, MAJOR conferences whose target audience includes professionals who work in, develop, implement and/or support CME/CE/CPD and QI for healthcare professionals; and live, MAJOR conferences of societies whose members include under-represented or minority healthcare professionals.

Questions? Email IGLC@pfizer.com